Cardiff Oncology Inc (CRDF) Actualités

Form 8-K - Current report

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the...

Form 8-K - Current report

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut...

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

- Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through...

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update

- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material